ESTA · Establishment Labs Holdings Inc.
$71.52
-3.84 (-5.10%)
At close · Aug 20
Market Cap
$2.25B
Shares
29.80M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$71.52
Open$74.92
Day$71.02–75.65
52W close$36.84–95.65
Avg vol 30d503K
Short int4.3M · 14.6% float · 9.9d
Short vol76%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−2%
below
Price vs 50-day avg
−17%
below
RSI (14)
30
neutral
MACD trend
Negative
52-week position
59%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−21%
trailing
6-month return
−9%
trailing
YTD return
−2%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $86 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +56 funds added
Insider flow
Distributing
Net -$6.6M over 90 days · 100% sells
Short interest
Falling
14.58% of float · ▼ -3.1% MoM · 9.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
198 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+76%
Y/Y
Gross margin
239%
contracting
EPS growth
+43%
Y/Y
Free cash flow
$-56.9M
Balance sheet
$75.6M
net cash
Quant / Vol
risk profile
Volatility
56%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Revenue guidance
· full-year 2026
Initiated
$269M – $271M
prior FY $211.08M
midpoint +27.9% Y/Y
Prior guidance
period ended
· from the 8-K filed Jan 12, 2026
Revenue
· fourth quarter of 2025
$64M – $65M
Full-year 2025 revenue
· fiscal year 2025
$210.5M – $211.5M
Year-end 2025 cash position
· year-end 2025
$75.5M
Guided vs delivered
· last 3 settled
Revenue
2025
guided at least $210M
$211.08M
In line
Revenue
2024
guided $174M – $184M
$166.03M
Miss −7.2%
Full-year revenue
full year 2023
guided $165M
$165.15M
Beat +0.1%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−2%
Neutral
Price vs 50-day avg
−17%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
59%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $86 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +56 funds added
Insider flow
Distributing
Net -$6.6M over 90 days · 100% sells
Short interest
Falling
14.58% of float · ▼ -3.1% MoM · 9.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
198 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $37
Now $72 · 59%
Range high $96
vs 200-day avg -2%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $3.7M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP EBITDA -$2.32M
+$3.14M Stock compensation expense & compensation paid in stock
+$697K Foreign currency (gain) loss
+$1.86M Third-party debt refinancing costs
+$321K Restructuring charges
= Adjusted EBITDA $3.69M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ESTA
this stock
Establishment Labs Holdings Inc.
|
$2.25B | -1.9% | +76.5% | — | 14.6% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$120.49B | -3.9% | +8.4% | 25.2 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -48.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ESTA | -5.4% | -21.5% | -9.1% | -22.7% | -1.9% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -3.4% | -24.8% | -20.3% | -24.8% | -13.7% |
Key facts
CIK
1688757
CUSIP
G31249108
13F (30d)
190 filings
185 filers
Visit website
Investor relations